Baxter International INC 8-K Filing
Ticker: BAX · Form: 8-K · Filed: Nov 25, 2025 · CIK: 10456
Sentiment: neutral
Filing Stats: 614 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2025-11-25 16:45:37
Key Financial Figures
- $1.00 — ge on which registered Common Stock, $1.00 par value BAX (NYSE) New York Stock Exc
Filing Documents
- bax-20251125.htm (8-K) — 32KB
- exhibit101-8xk112525closin.htm (EX-10.1) — 79KB
- 0001628280-25-054015.txt ( ) — 287KB
- bax-20251125.xsd (EX-101.SCH) — 3KB
- bax-20251125_def.xml (EX-101.DEF) — 17KB
- bax-20251125_lab.xml (EX-101.LAB) — 30KB
- bax-20251125_pre.xml (EX-101.PRE) — 18KB
- bax-20251125_htm.xml (XML) — 5KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. On November 25, 2025, Baxter International Inc. (" Baxter ") entered into an amendment (" Amendment No. 1 ") to the amended and restated five-year credit agreement dated June 11, 2025, among Baxter, as Borrower Representative, Baxter Healthcare SA and Baxter World Trade SRL, as Borrowers, various lenders and JPMorgan Chase Bank, N.A., as Administrative Agent (as amended by Amendment No. 1, the " Amended Credit Agreement "). The purpose of Amendment No. 1 is to amend the net leverage ratio covenant to increase the maximum net leverage ratio for the four fiscal quarters ending December 31, 2025, March 30, 2026, June 30, 2026, and September 30, 2026. The description above is a summary of Amendment No. 1 and is qualified in its entirety by the complete text of Amendment No. 1, a copy of which is attached to this report as Exhibit 10.1 and incorporated herein by reference. Capitalized terms used but not otherwise defined herein shall have the meaning as ascribed to them in the Amended Credit Agreement.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. 10.1 Amendment No. 1, dated as of November 25, 2025, to the Amended and Restated Five-Year Credit Agreement, dated as of June 11, 2025, among Baxter International Inc. as Borrower Representative, Baxter Healthcare SA, Baxter World Trade SRL, JPMorgan Chase Bank, National Association, as Administrative Agent, and certain other financial institutions named therein. (104) Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Baxter International Inc. Date: November 25, 2025 By: /s/ Ellen K. Bradford Name: Ellen K. Bradford Title: Senior Vice President and Corporate Secretary